VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: billkirn who wrote (1076)	7/30/1999 9:52:00 PM
From: Scott H. Davis	Read Replies (1) of 1972

All: A couple thoughts. A buyout is very likely due to the number of partnerings VICL has established. Great validation of technology, low burn rate, but trying to unwind the partnerings would be tough. Very disappointed the WSJ article did not mention VICL (I read it on the plane) But on squakbox this a.m. Joe Kearnan (sp?) spoke of VICL and it's naked DNA tech (I think he does most of the biotech comments there) Finally on the P&D reference - how totally absurd. P&D's are a OTC phenomenon, where the company it self puts out great sounding (to the unlearned) hinting about wonderfull things to come, negociatins, joint ventures... but never hard contract/$s kinda stuff. VICL and MRK do have a clear licensing agreement, involving real $s. One of the reasons they are so strong financially for a company that has several clinical trials going and no drugs/vaccines on the market yet. P&D? Get real. IMSCO Scott Vical jumps on report of Merck work on AIDS vaccine biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next